Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
MGNX's Cash-to-Debt is ranked higher than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.85
MGNX's Equity-to-Asset is ranked higher than
75% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MGNX: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
MGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.26  Med: 0.83 Max: 0.9
Current: 0.85
-0.26
0.9
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
66% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 9.17
Beneish M-Score: -0.97
WACC vs ROIC
26.23%
-1834.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -74.23
MGNX's Operating Margin % is ranked higher than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. MGNX: -74.23 )
Ranked among companies with meaningful Operating Margin % only.
MGNX' s Operating Margin % Range Over the Past 10 Years
Min: -80.16  Med: -9.69 Max: 12.86
Current: -74.23
-80.16
12.86
Net Margin % -72.26
MGNX's Net Margin % is ranked higher than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. MGNX: -72.26 )
Ranked among companies with meaningful Net Margin % only.
MGNX' s Net Margin % Range Over the Past 10 Years
Min: -80.16  Med: -10.21 Max: 13.1
Current: -72.26
-80.16
13.1
ROE % -23.18
MGNX's ROE % is ranked higher than
62% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. MGNX: -23.18 )
Ranked among companies with meaningful ROE % only.
MGNX' s ROE % Range Over the Past 10 Years
Min: -38.27  Med: -14.69 Max: -0.74
Current: -23.18
-38.27
-0.74
ROA % -20.31
MGNX's ROA % is ranked higher than
61% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. MGNX: -20.31 )
Ranked among companies with meaningful ROA % only.
MGNX' s ROA % Range Over the Past 10 Years
Min: -25.57  Med: -3.93 Max: 14.36
Current: -20.31
-25.57
14.36
ROC (Joel Greenblatt) % -225.78
MGNX's ROC (Joel Greenblatt) % is ranked higher than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. MGNX: -225.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -648.31  Med: -88.92 Max: 250.31
Current: -225.78
-648.31
250.31
3-Year Revenue Growth Rate -32.10
MGNX's 3-Year Revenue Growth Rate is ranked lower than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. MGNX: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.5  Med: -62.2 Max: -32.1
Current: -32.1
-68.5
-32.1
3-Year EPS without NRI Growth Rate 248.30
MGNX's 3-Year EPS without NRI Growth Rate is ranked higher than
100% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MGNX: 248.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 248.3
Current: 248.3
0
248.3
GuruFocus has detected 2 Warning Signs with Macrogenics Inc $MGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MGNX's 30-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MGNX Guru Trades in Q2 2016

Paul Tudor Jones 12,858 sh (New)
Steven Cohen 2,554,900 sh (+9.64%)
John Griffin 1,360,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
First Eagle Investment 221,800 sh (-22.39%)
Julian Robertson 313,140 sh (-45.55%)
Ronald Muhlenkamp 15,835 sh (-76.45%)
» More
Q3 2016

MGNX Guru Trades in Q3 2016

Paul Tudor Jones 15,542 sh (+20.87%)
First Eagle Investment 221,800 sh (unchged)
John Griffin 1,360,000 sh (unchged)
Julian Robertson 266,067 sh (-15.03%)
Ronald Muhlenkamp 12,162 sh (-23.20%)
Steven Cohen 1,813,300 sh (-29.03%)
» More
Q4 2016

MGNX Guru Trades in Q4 2016

Ronald Muhlenkamp 12,803 sh (+5.27%)
John Griffin 1,360,000 sh (unchged)
Paul Tudor Jones 14,959 sh (-3.75%)
Julian Robertson 239,667 sh (-9.92%)
First Eagle Investment 175,000 sh (-21.10%)
Steven Cohen 1,213,117 sh (-33.10%)
» More
Q1 2017

MGNX Guru Trades in Q1 2017

Jim Simons 130,923 sh (New)
Ronald Muhlenkamp 13,167 sh (+2.84%)
John Griffin 1,360,000 sh (unchged)
Julian Robertson 239,667 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen 1,180,817 sh (-2.66%)
Paul Tudor Jones 13,759 sh (-8.02%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ADRO, OTCPK:IPHYF, NAS:ANIK, NYSE:MYOV, NAS:JNCE, NAS:OMER, NAS:KERX, NAS:MESO, NAS:ACOR, NAS:ACRS, NAS:AMAG, NAS:EDIT, NAS:AMRI, NAS:CYTK, NAS:LJPC, NAS:ESPR, NYSE:BHVN, NAS:BYSI, NAS:VNDA, NAS:TGTX » details
Traded in other countries:M55.Germany,
Headquarter Location:USA
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Top Ranked Articles about Macrogenics Inc

MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results
MacroGenics Announces Registered Direct Offering of Common Stock
MacroGenics to Present at Two Upcoming Investor Conferences in May
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017
MacroGenics to Present at the Needham Healthcare Conference

Rockville, MD, March 29, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. ( MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company's management will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday April 5, 2017 at 8:40 am ET. A webcast of MacroGenics' presentation may be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days after the conference. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
Contacts:

Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, [email protected]

Karen Sharma, Senior Vice President
MacDougall Biomedical Communications
1-781-235-3060, [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.89
MGNX's PB Ratio is ranked higher than
68% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. MGNX: 2.89 )
Ranked among companies with meaningful PB Ratio only.
MGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 3.51 Max: 12.83
Current: 2.89
1.73
12.83
PS Ratio 7.66
MGNX's PS Ratio is ranked higher than
62% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. MGNX: 7.66 )
Ranked among companies with meaningful PS Ratio only.
MGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.21  Med: 9.08 Max: 24.92
Current: 7.66
1.21
24.92
EV-to-EBIT -6.78
MGNX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. MGNX: -6.78 )
Ranked among companies with meaningful EV-to-EBIT only.
MGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77  Med: -9.9 Max: 2441.2
Current: -6.78
-77
2441.2
EV-to-EBITDA -7.65
MGNX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. MGNX: -7.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
MGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.8  Med: -11.45 Max: 573.9
Current: -7.65
-96.8
573.9
Current Ratio 9.45
MGNX's Current Ratio is ranked higher than
80% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. MGNX: 9.45 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 9.45 Max: 17.84
Current: 9.45
1.35
17.84
Quick Ratio 9.45
MGNX's Quick Ratio is ranked higher than
80% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MGNX: 9.45 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.35  Med: 9.45 Max: 17.84
Current: 9.45
1.35
17.84
Days Sales Outstanding 8.39
MGNX's Days Sales Outstanding is ranked higher than
88% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. MGNX: 8.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.43  Med: 12.15 Max: 22.41
Current: 8.39
4.43
22.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.50
MGNX's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. MGNX: -11.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -216.5  Med: -201.1 Max: -11.5
Current: -11.5
-216.5
-11.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.35
MGNX's Price-to-Net-Cash is ranked higher than
78% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. MGNX: 3.35 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 4.36 Max: 9.94
Current: 3.35
0
9.94
Price-to-Net-Current-Asset-Value 3.22
MGNX's Price-to-Net-Current-Asset-Value is ranked higher than
79% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. MGNX: 3.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 4.26 Max: 9.52
Current: 3.22
0
9.52
Price-to-Tangible-Book 2.89
MGNX's Price-to-Tangible-Book is ranked higher than
74% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. MGNX: 2.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.16  Med: 4.08 Max: 8.75
Current: 2.89
2.16
8.75
Price-to-Median-PS-Value 0.84
MGNX's Price-to-Median-PS-Value is ranked higher than
61% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. MGNX: 0.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.07 Max: 2.38
Current: 0.84
0
2.38
Earnings Yield (Greenblatt) % -14.75
MGNX's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. MGNX: -14.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.32  Med: 0.15 Max: 1.5
Current: -14.75
-15.32
1.5

More Statistics

Revenue (TTM) (Mil) $91.09
EPS (TTM) $ -1.93
Beta4.00
Short Percentage of Float11.31%
52-Week Range $16.75 - 33.30
Shares Outstanding (Mil)36.11

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 33 44 15
EPS ($) -3.78 -3.74 -4.44
EPS without NRI ($) -3.78 -3.74 -4.44
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results May 03 2017 
MacroGenics Announces Registered Direct Offering of Common Stock Apr 27 2017 
MacroGenics to Present at Two Upcoming Investor Conferences in May Apr 26 2017 
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call Apr 25 2017 
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017 Mar 31 2017 
MacroGenics to Present at the Needham Healthcare Conference Mar 29 2017 
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple Aug 15 2016 
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 22, 2017 May 22 2017
ETFs with exposure to MacroGenics, Inc. : May 8, 2017 May 08 2017
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 May 05 2017
MacroGenics reports 1Q loss May 03 2017
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results May 03 2017
Investor Network: MacroGenics, Inc. to Host Earnings Call May 03 2017
MacroGenics Announces Registered Direct Offering of Common Stock Apr 27 2017
MacroGenics to Present at Two Upcoming Investor Conferences in May Apr 26 2017
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call Apr 25 2017
MacroGenics, Inc. – Value Analysis (NASDAQ:MGNX) : April 19, 2017 Apr 19 2017
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : April 18, 2017 Apr 18 2017
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017 Mar 31 2017
MacroGenics to Present at the Needham Healthcare Conference Mar 29 2017
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : March 14, 2017 Mar 14 2017
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential Mar 03 2017
Edited Transcript of MGNX earnings conference call or presentation 28-Feb-17 9:30pm GMT Mar 01 2017
MacroGenics Provides Update on Corporate Progress and 2016 Financial Results Feb 28 2017
MacroGenics to Participate in Two Upcoming Investor Conferences Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat